Study: Omicron evades some but not all monoclonal antibodies

Several, but not all, of the human monoclonal antibodies used clinically to prevent patients from becoming severely ill from COVID-19 may not be protective against the omicron variant now sweeping across the United States, researchers reported Jan. 19 in the journal Nature Medicine.

Covid antibody treatments that don't work against omicron still being used in some states.

Atlas of currently available human neutralizing antibodies against SARS-CoV-2 and escape by Omicron sub-variants BA.1/BA.1.1/BA.2/BA.3 - ScienceDirect

New Omicron subvariant largely evades neutralizing antibodies

An infectious SARS-CoV-2 B.1.1.529 Omicron virus escapes neutralization by therapeutic monoclonal antibodies

SARS-CoV-2 Study Forecasts Emergence of Immune Escape Variants

New study suggests most monoclonal antibody treatments are ineffective against Omicron SARS-CoV-2 variant

Frontiers Impact of mAb-induced A475V substitution on viral fitness and antibody neutralization of SARS-CoV-2 omicron variants in the presence of monoclonal antibodies and human convalescent sera

Defining a de novo non-RBM antibody as RBD-8 and its synergistic rescue of immune-evaded antibodies to neutralize Omicron SARS-CoV-2

Omicron may not evade all monoclonal antibodies, lab study suggests, ET HealthWorld

FDA Limits Use of Monoclonal Antibodies to Treat COVID-19

Omicron Appears to Evade Vaccines Better Than Other Variants

Omicron variant evolution on vaccines and monoclonal antibodies

How Omicron escapes from antibodies, MIT News

The Omicron Variant Partly Dodged Vaccines In A Blood Study